Skip to content

Imaging study of using positron emission tomography for the effect of nootropics (atomoxetine, sertraline, paroxetine, benztropine) on the athletic performance

Imaging study of using positron emission tomography for the effect of nootropics (atomoxetine, sertraline, paroxetine, benztropine) on the athletic performance - PET imaging for the effect of atomoxetine, sertraline, paroxetine, and benztropine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000020150
Enrollment
20
Registered
2015-12-11
Start date
2015-12-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy adults

Interventions

Sponsors

Nippon Medical School
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: Subjects who have the ability to provide informed consent and adhere to the protocol. Subjects without the history of smoking.

Exclusion criteria

Exclusion criteria: Exclusion criteria: - with past or current history of psychiatric illness - with past or current history of serious medical illness and/or brain organic diseases - subject who is contraindicated for the use of MRI - with past or current history ofsevere liver disease, kidney disease, heart disease, allergy, or severe drug allergy - subject who are judged as not suitable for participation in this study

Design outcomes

Primary

MeasureTime frame
The effect of the nootropics on the monoaminergic neuron system (dopamine transporter).

Secondary

MeasureTime frame
blood and/or urine concentration, MRI

Countries

Japan

Contacts

Public ContactAmane Tateno

Nippon Medical School Department of Neuropsychiatry

amtatneo@nms.ac.jp+81-3-3822-2131

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026